Here is the link to take you back to the old msg baord
Whenever you want to go to some board replaced the exel by that stock symbol. also type in http://
IBb and XBI collapsed. All drug stocks are down 50% or more. Incyte is the best of developing biotech breed
Every Friday is a buyout rumor day. Every Monday morning I'm so excited but only to be disappointed ( sarcasm intended)
Good luck! It will never hit there pending a bad news. Biotech sector is coming up. If you think about it everything except biotech and oil were running up . Now those are overbought and people are looking for bargains and people are looking at biotech. Oil ran way too much in short time so there is no reason to put money there.
By the way it just ran up to 150 after you sold. Tells you that you should never chase stock in hopes of buyout.
maybe two completely different drug and hence difference of opinion. Ocaliva targets PBC/NASH liver disease and it makes sense that they hired Gilead's point person for HepC launch in Europe.
Jermasek was instrumental in establishing renal business for KErx so perfect fit for both.
Exactly...And here is the quote
"And then the other question was, why do I believe that simtuzumab will work in liver fibrosis even though it hasn’t shown to be active in IPF myelofibrosis and in tumors. What a simple reason is you could make an argument and therefore fibrosis is different from IPL. Buy having that said it is somewhat liver fibrosis it’s different from IPF. But having that said, it somewhat diminishes my enthusiasm about simtuzumab, because it’s simply hasn’t shown any activity yet in any of the diseases that we chose to do"
So Even Bischofberger think that this is a really a toss up now with deck stacked heavily against it. it is going to fail in both..mark it down.
Gilead is looking into PSC with their simtuzumab. PSC is brother disease of PBC. SO if they success in PSC they will succeed in PBC as well.
Again a lit. Here is the actual quote" CA is a bile acid and bile acids do many things in your body and side effects that we’re seeing the rash". FDA approved OCA for PBC...where Rash is actually one of the symptoms. So another lie for you.
"There was also a side effect of reducing HDL fairly substantially and we have the philosophy instead of dealing with an orally absorbed systemically active bile acid analog we have an FXR agonist that’s minimally, orally absorbed that simply works into GI and releases FGF19."
Again no words of bad safety profile. The drug will be absorbed in liver and guess where is the HDL/LDL is processed..in the liver. So where you have a targeted approach it wills till end up interfering the lipid processing if it hits the same pathway.
Divray you are such a big lier and then you have audacity to claim that you are fact abased.
And this is a blatant lie. He did not refer to any drug esp about OCA and never mentioned the safety profile.
It's OK. Ultimately you have to do your own homework and be fine with your position. I'm good with my position
I am not sure. Generally bioteck sector is looking up. Trump and CLlnton are tearing into each other so it is less policy and more barking. Oil money has been made. I would not short here because the risk is too high. Look at IBB for clues.
And Jonathan Silverstein is the managing partner of Orbimed who made this investment. He also has and I quote"1,259 shares of common stock and options to purchase 15,327 shares of common stock that are exercisable within 60 days of May 23, 2016 that are held directly by Mr. Silverstein. Look at the date 23rd May2016. Calculate 60 days from here that takes us to July 26th. If he exercises his right to buy you could bet your house that buyout is in process in next 2 months after July 26th .
None of the insiders have sold any shares after approval. They could have easily timed it esp Dr. Shapiro. If you go back and look in the past every major run up has saw insiders esp Shapiro unloading few shares. That will tell you something.
Second look at the ownership of the shares. Orbimed is almost a 55 owner and I'm delightfully surprise to see FMT with 14% ownership of share! That is again a vote of confidence.
Third the pipeline is exciting. Look at harvoni/Sovaldi. Gilead made money of 1st Generation and the of 2nd generation and are right behind the 3rd generation combo. if there second molecule pans out they will have a long sustainable drug product with potential combination. Gilead also has atleast three other drugs that target other receptors in the same pathway so combinations are more likely to happen.
i know some of you have been playing weekly buyout games. It will not do you good. You buy and hold your core and make money on trading your shares.
buyout will happen before year end. My timeline is August/September when they have some idea on the new molecule is #$%$ and how the lipid studies are going on.
If you are looking for buyout candidates here are coupleof nuggets. Always look for companies who have de-risked drugs that means they have done atleast phase 2 with a clear efficacy signal. Second they lack commercial infrastructure to launch drugs by themselves. third they have fewer competitors int he same disease with potential to launch in other indications. This applies to a lesser extend to oncology companies but still is true.
Also one critical problem with Provenge was the manufacturing cost. It was expensive and not any operating margin left int here to make any money. This will be a pill so easy. The real money make will be NASH. if it hits NASH, lipid trial shows no safety concern and the second compound is better than OCA then we can say this will be 500 dollar stock at minimum.
People who have insurance and want to stay alive will pay the price. The good thing is insurance cover most of it. And people who don't have insurance can always go through charity and get the cost reduced.
What! That is just a buffoonery argument you provided. Go back and check the cost of MS drugs as well as Oncology. Look at the total care that goes into costs. Insurance never pays what the list price is. It is always negotiated and to reduce the companies provide rebates.
From your argument it is clear that you are a short or long Genfit. Good luck.